Literature DB >> 32795418

Parallel Discovery Strategies Provide a Basis for Riboswitch Ligand Design.

Brandon Tran1, Patricio Pichling1, Logan Tenney2, Colleen M Connelly2, Michelle H Moon2, Adrian R Ferré-D'Amaré1, John S Schneekloth3, Christopher P Jones4.   

Abstract

Riboswitches are mRNA domains that make gene-regulatory decisions upon binding their cognate ligands. Bacterial riboswitches that specifically recognize 5-aminoimidazole-4-carboxamide riboside 5'-monophosphate (ZMP) and 5'-triphosphate (ZTP) regulate genes involved in folate and purine metabolism. Now, we have developed synthetic ligands targeting ZTP riboswitches by replacing the sugar-phosphate moiety of ZMP with various functional groups, including simple heterocycles. Despite losing hydrogen bonds from ZMP, these analogs bind ZTP riboswitches with similar affinities as the natural ligand, and activate transcription more strongly than ZMP in vitro. The most active ligand stimulates gene expression ∼3 times more than ZMP in a live Escherichia coli reporter. Co-crystal structures of the Fusobacterium ulcerans ZTP riboswitch bound to synthetic ligands suggest stacking of their pyridine moieties on a conserved RNA nucleobase primarily determines their higher activity. Altogether, these findings guide future design of improved riboswitch activators and yield insights into how RNA-targeted ligand discovery may proceed. Published by Elsevier Ltd.

Entities:  

Keywords:  RNA; X-ray crystallography; kinetic control; microarray; small molecule; structure; target-based design; transcription

Mesh:

Substances:

Year:  2020        PMID: 32795418      PMCID: PMC7709957          DOI: 10.1016/j.chembiol.2020.07.021

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  50 in total

Review 1.  The promise of riboswitches as potential antibacterial drug targets.

Authors:  Christina E Lünse; Anna Schüller; Günter Mayer
Journal:  Int J Med Microbiol       Date:  2013-09-04       Impact factor: 3.473

2.  The kinetics of ligand binding by an adenine-sensing riboswitch.

Authors:  J Kenneth Wickiser; Ming T Cheah; Ronald R Breaker; Donald M Crothers
Journal:  Biochemistry       Date:  2005-10-11       Impact factor: 3.162

3.  Use of cis- and trans-ribozymes to remove 5' and 3' heterogeneities from milligrams of in vitro transcribed RNA.

Authors:  A R Ferré-D'Amaré; J A Doudna
Journal:  Nucleic Acids Res       Date:  1996-03-01       Impact factor: 16.971

4.  Purine analogs targeting the guanine riboswitch as potential antibiotics against Clostridioides difficile.

Authors:  Lok-Hang Yan; Antoine Le Roux; Kumaraswamy Boyapelly; Anne-Marie Lamontagne; Marie-Ann Archambault; Frédéric Picard-Jean; David Lalonde-Seguin; Emilie St-Pierre; Rafael J Najmanovich; Louis-Charles Fortier; Daniel Lafontaine; Éric Marsault
Journal:  Eur J Med Chem       Date:  2017-12-02       Impact factor: 6.514

5.  A disconnect between high-affinity binding and efficient regulation by antifolates and purines in the tetrahydrofolate riboswitch.

Authors:  Jeremiah J Trausch; Robert T Batey
Journal:  Chem Biol       Date:  2014-01-02

6.  An ancient riboswitch class in bacteria regulates purine biosynthesis and one-carbon metabolism.

Authors:  Peter B Kim; James W Nelson; Ronald R Breaker
Journal:  Mol Cell       Date:  2015-01-22       Impact factor: 17.970

7.  Validating fragment-based drug discovery for biological RNAs: lead fragments bind and remodel the TPP riboswitch specifically.

Authors:  Katherine Deigan Warner; Philip Homan; Kevin M Weeks; Alison G Smith; Chris Abell; Adrian R Ferré-D'Amaré
Journal:  Chem Biol       Date:  2014-04-24

Review 8.  Principles for targeting RNA with drug-like small molecules.

Authors:  Katherine Deigan Warner; Christine E Hajdin; Kevin M Weeks
Journal:  Nat Rev Drug Discov       Date:  2018-07-06       Impact factor: 84.694

9.  Synthetic ligands for PreQ1 riboswitches provide structural and mechanistic insights into targeting RNA tertiary structure.

Authors:  Colleen M Connelly; Tomoyuki Numata; Robert E Boer; Michelle H Moon; Ranu S Sinniah; Joseph J Barchi; Adrian R Ferré-D'Amaré; John S Schneekloth
Journal:  Nat Commun       Date:  2019-04-02       Impact factor: 14.919

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  6 in total

1.  RNA-Ligand Interactions Quantified by Surface Plasmon Resonance with Reference Subtraction.

Authors:  J Winston Arney; Kevin M Weeks
Journal:  Biochemistry       Date:  2022-07-08       Impact factor: 3.321

2.  Enhanced cobalamin biosynthesis in Ensifer adhaerens by regulation of key genes with gradient promoters.

Authors:  Sha Xu; Zhiqiang Xiao; Shiqin Yu; Weizhu Zeng; Yongming Zhu; Jingwen Zhou
Journal:  Synth Syst Biotechnol       Date:  2022-05-04

Review 3.  Small molecule targeting of biologically relevant RNA tertiary and quaternary structures.

Authors:  Martina Zafferani; Amanda E Hargrove
Journal:  Cell Chem Biol       Date:  2021-04-05       Impact factor: 8.116

4.  Subsite Ligand Recognition and Cooperativity in the TPP Riboswitch: Implications for Fragment-Linking in RNA Ligand Discovery.

Authors:  Meredith J Zeller; Ashok Nuthanakanti; Kelin Li; Jeffrey Aubé; Alexander Serganov; Kevin M Weeks
Journal:  ACS Chem Biol       Date:  2022-01-21       Impact factor: 5.100

5.  Synthesis of RNA-based gene regulatory devices for redirecting cellular signaling events mediated by p53.

Authors:  Xinbo Huang; Mingxia Wang; Yuchen Liu; Yaoting Gui
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

Review 6.  Targeting RNA structures with small molecules.

Authors:  Jessica L Childs-Disney; Xueyi Yang; Quentin M R Gibaut; Yuquan Tong; Robert T Batey; Matthew D Disney
Journal:  Nat Rev Drug Discov       Date:  2022-08-08       Impact factor: 112.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.